Stay updated with BYDFi's latest crypto news, covering Bitcoin, Ethereum, XRP, Solana, Dogecoin, market trends, regulatory updates, on-chain movements, and trading-related developments. This news hub is updated regularly to help readers follow major market stories and discover deeper analysis by asset and topic.
The United States minted approximately 440,000 new millionaires in 2025, or about 1,200 each day, according to the latest UBS Global Wealth Report. The surge was driven primarily by rising financial m
Rivian Automotive (RIVN) shares fell 18.1% on July 7, marking the largest single-day drop since November 2024, after the electric-vehicle maker announced a new common-stock offering that underscores i
Corn futures posted gains of 3 to 4 cents on Wednesday morning, supported by a rally in the wheat complex, as traders weighed mixed U.S. crop conditions and updated Brazilian production estimates.
RBC Capital reaffirmed its Outperform rating on Verastem (NASDAQ:VSTM) on July 7, while lowering the price target from $15 to $14. The revised target still implies a potential upside of more than 211%
Sable Offshore Corp. (NYSE:SOC) still offers over 180% upside potential even after Jefferies slashed its price target from $24 to $11 on July 6. Analyst Lloyd Byrne maintained a Buy rating on the stoc
Larimar Therapeutics Inc. (NASDAQ:LRMR) has submitted the initial module of its Biologics License Application (BLA) to the U.S. Food and Drug Administration for Nomlabofusp, seeking accelerated approv
SAB Biotherapeutics Inc. (NASDAQ:SABS) has received a research grant from Breakthrough T1D to support a clinical trial of its experimental therapy SAB-142 in patients with Stage 3 type 1 diabetes. The
AtaiBeckley N.V. (NASDAQ:ATAI) has been named one of the 10 best stocks under $10 that could triple, according to a recent analysis. The clinical-stage biopharmaceutical company, focused on mental hea
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is among the top stocks under $10 that analysts believe could triple in value, driven by progress in its gene therapy pipeline. The company recently finalized the
Shabana Mahmood is poised to become Britain's next Chancellor of the Exchequer, according to reports from the Financial Times. The Labour politician is viewed as a fiscally disciplined centrist who pr